EyePoint Pharmaceuticals stock pivots to DME after wet AMD setback
Published on 11/10/2026 at 22:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEyePoint's strategic reset
- EyePoint is concentrating its development strategy on diabetic macular edema after setbacks in two wet AMD Phase III trials.
- The fully enrolled COMO and CAPRI studies are now the company's main clinical catalysts.
- Management is relying on VERONA Phase II results to support DURAVYU's potential in DME.
EyePoint Pharmaceuticals is redirecting its clinical strategy toward diabetic macular edema after its LUGANO and LUCIA Phase III wet age-related macular degeneration trials missed their primary non-inferiority endpoint. Investing.com reported the shift on Tuesday, November 10, 2026, after management discussed the company's priorities at the Stifel Healthcare Conference.
DME becomes the central catalyst
EyePoint said its two Phase III DME studies, COMO and CAPRI, are fully enrolled. The company is now presenting the program as its main route for DURAVYU, its investigational sustained-delivery treatment for retinal disease.
Chief Executive Jay Duker said the wet AMD trials showed biological activity but did not clear the primary visual-acuity threshold. Management argued that DME may offer a better fit because inflammation plays a larger role in the disease than in wet AMD.
VERONA supports the new strategy
EyePoint pointed to its Phase II VERONA study as support for the DME strategy. The company said the 2.7 milligram DURAVYU dose matched Eylea on visual acuity at 24 weeks, required fewer rescue injections and produced less retinal fluid on optical coherence tomography.
The company also said half of DURAVYU-treated eyes achieved complete DME resolution by the end of the study, compared with none in the Eylea arm. These findings are company-reported clinical observations rather than proof of success in the ongoing Phase III program.
Investors weigh execution risk
The strategic reset leaves investors focused on the COMO and CAPRI readout, the durability of the DME signal and EyePoint's ability to preserve capital while advancing the trials. The failed wet AMD endpoint raises the execution risk around the remaining development plan, even as management continues to emphasize safety, fluid control and treatment burden.
EyePoint Pharmaceuticals stock traded at 0.36 euros on Lang & Schwarz at 22:53 Berlin time on Tuesday, November 10, 2026.
EyePoint Pharmaceuticals stock facts
- Company: EyePoint Pharmaceuticals, Inc.
- ISIN: US30233G2093
- Ticker: EYPT
- Lang & Schwarz quote: 0.36 euros on Tuesday, November 10, 2026, at 22:53:46 Berlin time
- Lang & Schwarz change: 12.50 percent versus 0.32 euros
US equities provide the broader market backdrop for EyePoint through the S&P 500.
More news and analyses on EyePoint Pharmaceuticals stock.
